

**899 NORTH CAPITOL ST. NE – 2<sup>ND</sup> FLR.  
WASHINGTON, DC 20002**

**December 2, 2021**

**9:30 am**

**OPEN SESSION AGENDA  
(VIA ZOOM MEETING DUE TO THE COVID-19 PUBLIC HEALTH EMERGENCY)**

**Board of Pharmacy Mission Statement:**

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

**CALL TO ORDER:**

**PRESIDING:**

**BOARD MEMBERSHIP/ATTENDANCE:**

BOARD MEMBERS:		
	DR. TAMARA McCANTS, PHARM.D. R.PH CHAIRPERSON	
	MR. ALAN FRIEDMAN, R.PH, VICE CHAIRPERSON	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	DR. ASHLEE BOW, PHARM.D. R.PH	
	DR. ALLISON HILL, PHARM.D. R.PH	
	MR. GREGORY CENDANA, CONSUMER MEMBER	
STAFF:	DR. JUSTIN ORTIQUE, INTERIM EXECUTIVE DIRECTOR	
	KARIN BARRON, HEALTH LICENSING SPECIALIST	
	LUANNE GREENAWAY, PROGRAM SPECIALIST	
	COUNTEE GILLIAM, BOARD INVESTIGATOR	
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	
VISITORS:		

## Open Session Agenda

### Quorum:

<b>Introduction:</b>	Honoring Former Executive Director, Dr. Shauna White	
<b>1202-O-01</b>	<b><u>Approval of the Open Session Meeting Minutes for</u></b> October 7, 2021 November 4, 2021	
<b><u>Consent Agenda</u></b>	<b>None</b>	
<b><u>Chairperson Report</u></b>	<b><u>Interprofessional Workgroup</u></b>	Dr. Tamara McCants
<b><u>Executive Director Report</u></b>	<ul style="list-style-type: none"> <li>▪ <b>Statistical Report on Pharmacy professionals in the District of Columbia</b></li> <li>▪ <b>Prescription Drug Monitoring Program Updates</b></li> <li>▪ <b>DCRx (DC Center for Rational Prescribing)</b></li> <li>▪ <b>COVID-19 Vaccination Mandate</b></li> </ul>	Dr. Justin Ortique
<b><u>Senior Assistant General Counsel Report</u></b>		
<b>1202-O-02</b>	None	Ms. Carla Williams
<b><u>Subcommittee Reports</u></b>		
	<b><u>Legislative and Regulatory Subcommittee Report Items for Discussion</u></b>	Mr. Alan Friedman
<b>1202-O-03</b>	Draft Changes to the District Of Columbia Municipal Regulations For Pharmacies Chapter 19	
<b>1202-O-04</b>	Draft Changes to the District Of Columbia Municipal Regulations For Pharmacist Chapter 65	
<b>1202-O-05</b>	Draft Changes to the Health Occupations Revision Act (HORA)	
<b>1202-O-06</b>	Draft Changes to Chapter 13 Prescriptions And Distributions ("No Call State" language)	
<b>1202-O-07</b>	Workforce Survey	
<b>1202-O-08</b>	<b><u>Communications Subcommittee Report</u></b>	Dr. Ashlee Bow

<b><u>Matters for Consideration</u></b>		
1202-O-09	<p><b><u>Technician Trainee Participation in COVID-19 Testing</u></b>  <b><u>Jeenu Philip, Director, Pharmacy Affairs</u></b>  <b><u>Walgreen Co.</u></b></p> <p>(a) Email Communication</p>	
<b>NABP E-Newsletter</b>	<p><b><u>November 24, 2021</u></b></p> <p>DEA Proposes to Allow Transfer of Electronic Prescriptions for Schedules II-V CS Between Pharmacies for Initial Filling</p> <p>CDC Provisional Data Shows Record-High Drug Overdoses Driven by Fentanyl</p> <p>FDA Issues Warning to Avoid Compounded Products From Prescription Labs, Inc</p> <p>Drug Diversion Prevention Bill Signed Into Law</p> <p>Cold and Flu Toolkit Available to Raise Awareness on Safe Acetaminophen Use</p> <p><b><u>November 3, 2021</u></b></p> <p>FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Children Ages 5-11</p> <p>Nominate a Colleague or Board of Pharmacy for a 2022 NABP Award by December 31</p> <p>New Study Examines Increased Threat of Online Medication Sales Boosted From Social Media and COVID-19</p> <p>Recall Issued for CUBICIN Due to Presence of Glass Particles</p> <p>DEA's 'One Pill Can Kill' Campaign Helps Raise Awareness About Counterfeit Prescription Drugs</p> <p>More Than 400,000 Counterfeit N95 Masks Shipped to Cleveland Clinic, Some Employees Tested Positive For COVID-19</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link:  <a href="https://nabp.pharmacy/newsroom/news/">https://nabp.pharmacy/newsroom/news/</a>.</p>	Dr. Tamara McCants
<b><u>Comments from the Public</u></b>		

<p><b><u>Motion to Adjourn the Open Session</u></b></p>	<p>“Madam Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14).” ROLL CALL VOTE</p>	
---	---	--

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

**Open Session Meeting Adjourned at \_\_:\_\_ AM.**

**This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at [opengovoffice@dc.gov](mailto:opengovoffice@dc.gov).**